- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
1 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
VRTX | US$451.23 | -8.8% | 27.7% | US$115.4b | US$513.87 | PS10.9x | E47.4% | n/a | ||
LLY | US$753.41 | -7.2% | 26.6% | US$657.1b | US$992.18 | PE81.1x | E29.5% | 0.7% | ||
MLAB New | US$98.59 | -8.5% | 12.2% | US$541.8m | US$140.00 | PS2.3x | E124.8% | 0.6% | ||
VCYT | US$39.20 | -0.8% | 50.1% | US$3.0b | US$42.78 | PS7.1x | E45.6% | n/a | ||
RGEN | US$138.90 | -7.7% | -13.3% | US$7.2b | US$192.25 | PS12.3x | E50.9% | n/a | ||
BLFS | US$25.01 | 3.7% | 84.3% | US$1.0b | US$29.80 | PS7.9x | E72.5% | n/a | ||
CDXC | US$7.50 | 7.0% | 417.2% | US$575.7m | US$7.96 | PE386.6x | E81.8% | n/a |
Page 1 of 1